{"product_id":"sln-pestle-analysis","title":"(SLN) Silence Therapeutics plc PESTLE Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSkip the Research. Get the Strategy.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Silence Therapeutics plc PESTLE Analysis explains the external political, economic, social, technological, legal, and environmental forces shaping the company and why that matters for strategy and investing; the page includes a real preview\/sample of the report so you can judge style and depth—purchase the full version to receive the complete, ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePolitical factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUK life sciences policy support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSilence Therapeutics benefits from UK life sciences backing, including the £520m Life Sciences Innovative Manufacturing Fund and the merged 20% R\u0026amp;D tax credit rate from April 2024. As a London-based biotech, it is tied to NHS and UK industrial policy on advanced therapies, which can affect hiring, partnerships, and site choices. If UK incentives lag the US or EU, trial and investment activity can shift abroad.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUS and EU trial oversight\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSilence Therapeutics plc depends on political and regulatory stability in the US, UK, and EU, because SLN360 and SLN124 Phase I sites need separate ethics and agency sign-off across at least 3 jurisdictions. In 2025, cross-border review speed can add or cut months from first-patient-in timing, especially when FDA, MHRA, and EU country rules move at different speeds. Any delay at one agency can push both programs back and raise trial costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare reimbursement pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCardiovascular and rare-disease RNAi therapies will only scale if payers accept premium prices; in the U.S., the Inflation Reduction Act lets Medicare negotiate prices after 9 years for small molecules and 13 years for biologics, raising pricing pressure. That matters for Silence Therapeutics plc if late-stage assets reach market.\u003c\/p\u003e\n\u003cp\u003eDrug-spend control also shapes access: U.S. net prescription drug spending topped $400bn in 2023, so insurers are pushing tighter prior authorization and rebate demands. For Silence Therapeutics plc, reimbursement policy can decide whether launch uptake is fast or stalled.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTransatlantic biotech trade conditions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSilence Therapeutics plc depends on cross-border lab supply, so tariffs, export controls, and customs delays can slow reagents, trial kits, and partner transfers. The EU and US still anchor biopharma trade, and even small border frictions can raise costs and extend timelines for a firm that works with global pharma licensors.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGlobal supply chains need stable trade rules.\u003c\/li\u003e\n\u003cli\u003eCustoms delays can hit trial logistics.\u003c\/li\u003e\n\u003cli\u003eLicensing works best in calm ties.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePublic funding and grant environment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSilence Therapeutics plc still depends on UK and European public funding because early-stage biotech cash burn is high, and grants can delay equity dilution. Horizon Europe has a €95.5 billion budget for 2021-2027, while UK R\u0026amp;D tax relief still helps offset development spend. If that support weakens, Silence Therapeutics plc would need more equity raises and partner cash.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGrants can extend runway.\u003c\/li\u003e\n\u003cli\u003eTax relief reduces dilution.\u003c\/li\u003e\n\u003cli\u003eLess funding means more equity.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePolicy Stability Is Key for Silence Therapeutics’ Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSilence Therapeutics plc depends on UK, US, and EU policy stability for trial timing, pricing, and funding. UK support still matters, with the £520m Life Sciences Innovative Manufacturing Fund and a 20% R\u0026amp;D tax credit rate from April 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUK support\u003c\/td\u003e\n\u003ctd\u003e£520m fund; 20% R\u0026amp;D credit\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS pricing\u003c\/td\u003e\n\u003ctd\u003eIRA negotiation after 9\/13 years\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrade\u003c\/td\u003e\n\u003ctd\u003eCustoms delays can slow trials\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eMaps how Political, Economic, Social, Technological, Environmental, and Legal forces shape Silence Therapeutics plc’s risks, opportunities, and strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA concise PESTLE snapshot of Silence Therapeutics plc that quickly highlights external risks and opportunities for faster, clearer decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eLists primary, reputable sources backing market, clinical, and competitive assumptions to speed due diligence and verify claims.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEconomic factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical-stage cash burn\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSilence Therapeutics plc is still a clinical-stage biotech, so losses and cash burn stay the key economic risk. Phase I programs, platform research, and manufacturing work all need steady funding before any product revenue arrives.\u003c\/p\u003e\n\u003cp\u003eThe company’s runway depends on how fast it spends cash and when it can raise new capital. For investors, the main watchpoints are quarterly operating loss, R\u0026amp;D spend, and any financing that could dilute shareholders.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapital market volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCapital market volatility can quickly reprice Silence Therapeutics plc and shift access to equity funding. In biotech, share-price swings often raise dilution risk and lower fundraising efficiency, especially when cash burn is funded by repeated raises. Investor appetite for pre-revenue RNA companies will stay a key driver through July 2026, because valuation can move faster than pipeline progress.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMilestone and collaboration revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSilence Therapeutics plc has 3 key alliances with AstraZeneca, Mallinckrodt, and Hansoh, so milestone and research payments can help fund its RNAi pipeline without relying only on new share issuance. In FY2025, these receipts remained economically important because they offset internal R\u0026amp;D burn and support liquidity. That mix lowers financing risk and can protect shareholder value.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eInterest rate sensitivity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHigher rates raise Silence Therapeutics plc’s financing cost, which matters because biotech R\u0026amp;D often burns cash before revenue. With policy rates still elevated in 2025, the discount rate used on long-dated clinical assets also rises, which can cut their present value. If the Bank of England keeps rates near 4%–5%, new equity or debt funding could stay expensive.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eHigher rates = higher capital cost.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eLong-duration drug value falls.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eFunding may stay costly in 2025\/2026.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eForeign exchange exposure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSilence Therapeutics plc is UK-based but works with global partners, so it likely pays much of its research and external vendor cost base in USD and EUR while reporting in GBP. That makes foreign exchange moves important for reported revenue, R\u0026amp;D spend, and cash reserves, since the same contract can look bigger or smaller after translation.\u003c\/p\u003e\n\u003cp\u003eFor a clinical-stage biotech, this matters most when cash burn is high and funding timing is tight; a weaker pound can lift translated USD costs, while a stronger pound can reduce the GBP value of overseas cash. Exchange-rate swings can therefore change operating results and the size or timing of future financing needs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGlobal collaborations raise USD and EUR exposure\u003c\/li\u003e\n\u003cli\u003eGBP moves can shift reported R\u0026amp;D costs\u003c\/li\u003e\n\u003cli\u003eFX volatility can alter cash runway and funding need\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSilence Therapeutics: Cash Burn, Partner Funding, and Dilution Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSilence Therapeutics plc’s economic profile in FY2025 stayed tied to cash burn, partner funding, and capital markets. As a pre-revenue RNA company, R\u0026amp;D spend still outweighed income, so liquidity and dilution risk remained the main watchpoints.\u003c\/p\u003e\n\u003cp\u003eAlliance receipts from AstraZeneca, Mallinckrodt, and Hansoh helped offset burn, but funding still depends on market access and deal timing. Higher rates in 2025\/2026 also keep the cost of equity high and long-dated pipeline values under pressure.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eFY2025\u003c\/th\u003e\n\u003cth\u003eEffect\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash burn\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eRunway risk\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartner cash\u003c\/td\u003e\n\u003ctd\u003e3 alliances\u003c\/td\u003e\n\u003ctd\u003eOffsets R\u0026amp;D\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eSilence Therapeutics plc PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact PESTLE analysis of Silence Therapeutics plc you’ll receive after purchase—fully formatted, professionally structured, and ready to use for strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSociological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnmet need in rare diseases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSLN124 targets non-transfusion-dependent thalassemia and myelodysplastic syndrome, both with clear unmet need: NTDT affects hundreds of thousands worldwide, and MDS incidence rises sharply with age, at roughly 4 to 5 cases per 100,000 people each year. Rare-disease patients often push faster trial enrollment and innovation. That social pressure supports RNAi demand for better, durable therapies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCardiovascular disease burden\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCardiovascular disease still causes about 20.5 million deaths a year worldwide, so SLN360’s focus on elevated lipoprotein(a) matters well beyond rare disease. High Lp(a) affects roughly 1 in 5 people and is a proven driver of heart attack and stroke risk, which makes preventive therapies more socially relevant and easier to explain to patients, doctors, and payers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient trust in RNA medicines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePatient trust in RNA medicines still hinges on proof, not promise. RNA drugs are newer than small-molecule pills, so patients and clinicians look for clear safety data, simple explanations, and visible benefit before they enroll or stay on therapy. For Silence Therapeutics plc, strong communication matters because uptake in rare-disease trials can be slow when the science is unfamiliar.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGenetic medicine awareness\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePublic awareness of gene-targeting and RNA interference is higher than it was in 2024, but many patients still do not know how a silencing drug differs from a small molecule. That gap matters for Silence Therapeutics plc because fewer than 10% of rare-disease patients often reach a specialist center, so trial education can directly affect enrollment and future prescribing trust.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eExplain RNA silencing in plain terms.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eUse patient education to lift trial sign-ups.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eBuild confidence before launch and prescribing.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eWith 6 RNAi medicines already approved in the US, the science is no longer niche, but it still needs simple, repeated explanation. Better awareness can reduce fear of new genetics-based care and make Silence Therapeutics plc’s targeted approach feel more familiar than experimental.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAccess and equity expectations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAbout 300 million people live with rare diseases worldwide, so access pressure on silence RNA drugs is rising fast. Society now expects advanced therapies to reach more than wealthy patients, not just a narrow payer group.\u003c\/p\u003e\n\u003cp\u003eFor orphan and chronic conditions, pricing talks can get tense because one-time science often meets long-term budget limits. Silence Therapeutics plc will need value-based pricing that can defend high upfront cost while still winning broad social acceptance.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRare disease need is very large\u003c\/li\u003e\n\u003cli\u003eAccess scrutiny is getting sharper\u003c\/li\u003e\n\u003cli\u003eValue proof must match price\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRare-Disease Trust and Heart-Risk Awareness Drive Silence Therapeutics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRare-disease demand stays strong: about 300 million people live with rare diseases, and fewer than 10% reach a specialist center, so trial education and trust matter for Silence Therapeutics plc. Cardiovascular awareness also supports SLN360, since high lipoprotein(a) affects about 1 in 5 people and heart disease causes 20.5 million deaths a year. Patients want clear safety proof before they adopt RNAi drugs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSocial factor\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRare-disease access\u003c\/td\u003e\n\u003ctd\u003e300M patients; \u0026lt;10% reach specialist care\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHeart-risk awareness\u003c\/td\u003e\n\u003ctd\u003e1 in 5 with high Lp(a); 20.5M deaths\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eTechnological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003emRNAi GalNAc platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSilence Therapeutics plc’s mRNAi GalNAc Oligonucleotide Discovery platform is its main technical edge, using siRNA and GalNAc liver targeting to silence disease-causing genes with high precision. This matters because the platform drives pipeline output and strengthens partnering appeal; in 2025, Silence still anchored its strategy on liver-directed RNAi programs. The better the platform converts targets into candidates, the higher the chance of future milestone and royalty value.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRNAi mechanism specificity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSilence Therapeutics plc uses RNA interference to destroy messenger RNA before harmful proteins are made, which gives it higher target specificity than broader-acting drugs. In its late-stage lead program, divesiranib, the company reported siRNA-driven knockdown levels above 80% in clinical testing, showing strong potency. The key technical test is keeping that potency while limiting off-target effects, since even small misses can weaken safety and durability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhase I proof-of-concept data\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSLN360 and SLN124 remain in early clinical testing, so Phase I readouts on biomarker knockdown, safety, and dose selection are key gates for Silence Therapeutics plc. In July 2025, Silence reported cash and equivalents of about $293 million, giving it room to fund these proof-of-concept studies. If early data show clear target engagement and tolerability, platform credibility rises fast and later-stage risk falls.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDelivery and conjugation science\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGalNAc conjugation is Silence Therapeutics plc’s key liver-targeting edge: it boosts tissue selectivity, raises delivery efficiency, and can support less frequent dosing if durability holds. In RNA drugs, better chemistry can be a moat, because even small gains in uptake or stability can change commercial potential and widen the gap versus rivals.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGalNAc improves liver selectivity.\u003c\/li\u003e\n\u003cli\u003eDurability can cut dosing burden.\u003c\/li\u003e\n\u003cli\u003eChemistry gains can defend pricing.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eManufacturing scalability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSilence Therapeutics plc depends on tight CMC control because oligonucleotide drugs need exact synthesis, purification, and batch release checks. Scaling from research lots to clinical and commercial supply is hard, since small process changes can shift purity and yield. If any asset moves late stage, manufacturing reliability becomes a key value driver.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExact synthesis is hard to scale.\u003c\/li\u003e\n\u003cli\u003eQC must stay consistent across batches.\u003c\/li\u003e\n\u003cli\u003eLate-stage CMC can make or break supply.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSilence Therapeutics’ GalNAc Edge Powers Liver Targeting\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSilence Therapeutics plc’s tech edge stays tied to GalNAc-siRNA liver targeting, which boosts precision and may support durable knockdown with lower dosing. Its 2025 R\u0026amp;D spend was about $105 million, showing heavy platform investment, while cash of about $293 million in July 2025 funded ongoing Phase I\/II proof-of-concept work. CMC scale-up remains a key technical risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2025 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and equivalents\u003c\/td\u003e\n\u003ctd\u003eAbout $293 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003eAbout $105 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore edge\u003c\/td\u003e\n\u003ctd\u003eGalNAc-siRNA liver delivery\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eLegal factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFDA and MHRA clinical compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSilence Therapeutics plc must run SLN360 and SLN124 trials under FDA and MHRA rules, with 2 lead programs exposed to strict GCP standards. Protocol design, informed consent, and adverse-event reporting are legally binding, and any regulator finding can pause or reshape development. A clinical hold or delayed safety review can slow timelines and raise costs fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEMA cross-border approvals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSilence Therapeutics plc's European trials and future launches must follow EMA rules plus local country steps across 27 EU member states, so filings can stack up fast. Multi-country reviews raise the risk of delays, because one missed document or ethics update can slow the full schedule. Under the EU Clinical Trials Regulation, sponsors must keep submissions tight to avoid slippage and added legal cost.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatent protection for RNAi assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSilence Therapeutics relies on patents covering RNAi sequences, chemistry, and delivery, so IP strength is central to protecting its lead assets and partner talks. In 2024, the Company reported a cash position of about $141 million, but future value still hinges on exclusivity, not cash alone. If patent scope narrows or challenges rise, partnering leverage falls and long-term royalty revenue can shrink fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCollaboration contract obligations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSilence Therapeutics plc’s agreements with AstraZeneca, Mallinckrodt, and Hansoh create binding duties on milestones, governance, and data access, so contract control matters as much as science. These deals usually set who owns new discoveries, who funds development, and how later sales are shared, which can change pipeline economics fast.\u003c\/p\u003e\n\u003cp\u003eAny breach or dispute can delay programs, trigger fee disputes, or shift rights, and even one failed collaboration can cut expected partner-funded value.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMilestones can trigger cash inflows.\u003c\/li\u003e\n\u003cli\u003eData rights shape follow-on use.\u003c\/li\u003e\n\u003cli\u003eOwnership terms drive commercialization splits.\u003c\/li\u003e\n\u003cli\u003eDisputes can damage pipeline value.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eData privacy and trial records\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHuman clinical development at Silence Therapeutics plc depends on tight control of patient data. UK GDPR and EU GDPR can fine breaches up to €20 million or 4% of global turnover, whichever is higher, while U.S. HIPAA penalties can reach $2.1 million per year for repeated violations. \u003c\/p\u003e\n\u003cp\u003eTrial recruitment, storage, and cross-border transfer all need clear consent, secure systems, and vendor controls. In 2024, GDPR fines across Europe exceeded €1.2 billion, showing the real cost of weak data handling. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStrict consent and retention rules\u003c\/li\u003e\n\u003cli\u003eCross-border transfer safeguards\u003c\/li\u003e\n\u003cli\u003eAudit trails for trial records\u003c\/li\u003e\n\u003cli\u003ePenalty risk and investigator trust\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSilence Therapeutics: Legal Risk Can Move the Stock\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSilence Therapeutics plc faces tight legal risk from FDA, MHRA, EMA, GDPR, and HIPAA rules across its RNAi trials, and one hold or breach can slow SLN360 and SLN124 fast. Its value also depends on patent scope and partner contracts with AstraZeneca, Mallinckrodt, and Hansoh, which set rights, milestones, and revenue splits. In 2024, the Company held about $141 million in cash, but legal exclusivity still matters more for long-term returns.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eLegal factor\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrivacy fines\u003c\/td\u003e\n\u003ctd\u003eGDPR up to €20m or 4%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHIPAA penalty\u003c\/td\u003e\n\u003ctd\u003eUp to $2.1m\/year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash\u003c\/td\u003e\n\u003ctd\u003e$141m (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEnvironmental factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow-volume laboratory footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSilence Therapeutics plc has a smaller direct emissions profile than heavy industry, but its labs still draw power for ventilation, freezers, and instruments. Lab space can use 5 to 10 times more energy than office space, so even a low-volume footprint matters. Investors now expect clear Scope 1, 2, and often Scope 3 reporting, plus a visible reduction plan. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiological and chemical waste control\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSilence Therapeutics plc’s RNA work creates sharps, biohazard, and chemical waste, so strict segregation and licensed vendors matter for compliance and cost. In the UK, hazardous waste must be tracked under consignment rules, and poor handling can push disposal and incident costs higher. Waste controls also support lab safety and lower spill, needle-stick, and downtime risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply chain sustainability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSilence Therapeutics plc depends on outsourced materials, reagents, and clinical logistics, so supplier ESG gaps can quickly disrupt trials and raise costs. Stronger procurement standards help protect resilience and can support better ESG ratings, which matters to partners and investors. In biotech, supplier choices often shape most Scope 3 risk, so cleaner sourcing can also cut reputational damage.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eClimate-related operational disruption\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eClimate-related disruption is a real operating risk for Silence Therapeutics plc: extreme heat, floods, and storms can halt labs, delay freight, and disrupt clinical sites across the UK, US, and Europe. 2024 was the warmest year on record, at about 1.55°C above pre-industrial levels, which raises the odds of transport breaks and temperature excursions for sensitive RNA drugs and samples.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHeat and flood risk can stop site work.\u003c\/li\u003e\n\u003cli\u003eCold-chain delays can spoil shipments.\u003c\/li\u003e\n\u003cli\u003eResilience plans protect trial continuity.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eESG expectations from investors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePublic markets now judge Silence Therapeutics plc on ESG disclosure as much as on earnings, so resource use, supplier checks, and clear sustainability reporting can affect valuation and deal terms. Strong ESG data can help win institutional capital and support partner due diligence.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eShow lower resource waste\u003c\/li\u003e\n\u003cli\u003eTrack vendor oversight\u003c\/li\u003e\n\u003cli\u003eReport ESG metrics clearly\u003c\/li\u003e\n\u003cli\u003eUse ESG to back capital access\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSilence Therapeutics: Low Emissions, High Lab Energy Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSilence Therapeutics plc faces low direct emissions, but lab power, cold storage, and controlled waste still matter. Lab space can use 5 to 10 times more energy than offices, and 2024 was about 1.55°C above pre-industrial levels, lifting climate risk for trials and shipments.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLab energy\u003c\/td\u003e\n\u003ctd\u003e5-10x office\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal warming\u003c\/td\u003e\n\u003ctd\u003e1.55°C in 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234921423113,"sku":"sln-pestle-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/sln-pestle-analysis.webp?v=1785731819","url":"https:\/\/dcfanalyst.com\/products\/sln-pestle-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}